Voyager Acquisition Corp and VERAXA Biotech Announce Form F-4 Filing for Proposed Business Combination

Viveon Health Acquisition Corp. to Merge with Suneva Medical

January 12, 2022

Medical Devices

Suneva Medical, a San Diego–based regenerative aesthetics medical technology company, has entered into a definitive merger agreement with special purpose acquisition company Viveon Health Acquisition Corp. The transaction will combine Suneva with the public SPAC vehicle (NYSE American: VHAQ) to provide growth capital and public-market access for Suneva, with the combined company expected to trade on the NYSE under the symbol "RNEW."

AstraZeneca Acquires Icosavax

December 12, 2023

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Icosavax, a Seattle-based clinical-stage biopharmaceutical company, in a cash tender offer valuing the deal at approximately $0.8bn upfront and up to $1.1bn including contingent payments. The acquisition brings Icosavax's virus‑like particle (VLP) platform and Phase III‑ready combination RSV/hMPV vaccine candidate IVX‑A12 into AstraZeneca's Vaccines & Immune Therapies late‑stage pipeline to strengthen respiratory vaccine capabilities for older adults and vulnerable populations.

Veranex Acquires Fusion Biotec

December 13, 2022

Medical Devices

Veranex has acquired Fusion Biotec, a Southern California design and engineering firm specializing in complex electro-mechanical diagnostic instrumentation and medical devices. The acquisition brings Fusion's 15,000-square-foot facility and 45+ engineering staff into Veranex's Product Design & Engineering capabilities, expanding Veranex's diagnostic/IVD development, software/firmware reuse and Southern California footprint; financial terms were not disclosed.

Nevro Corp. Acquires Vyrsa Technologies

November 30, 2023

Medical Devices

Nevro Corp. acquired Vyrsa Technologies, a privately held medical technology company focused on minimally invasive sacroiliac (SI) joint fusion devices, in a deal that closed November 30, 2023. Nevro paid $40 million at closing and may pay up to an additional $35 million in cash or stock tied to development and sales milestones; the company said Vyrsa will broaden its product portfolio and is projected to be accretive in 2024.

OceanTech Acquisitions I Corp and Captura Biopharma Sign Definitive Business Combination Agreement

August 10, 2022

Biotechnology

OceanTech Acquisitions I Corp., a special purpose acquisition company, signed a definitive merger agreement with Captura Biopharma to take the biotech company public. The combined company is expected to operate under the name Captura Biopharma Holdings, Inc. and remain listed on Nasdaq, subject to SEC, regulatory, and stockholder approvals.

Quanterix Completes Acquisition of Akoya Biosciences (Amended Merger)

July 8, 2025

Healthcare Services

Quanterix (NASDAQ: QTRX) acquired Akoya Biosciences (NASDAQ: AKYA) under an amended merger agreement, issuing about 7.8 million shares and paying approximately $20 million in cash to Akoya holders. The amended terms changed the consideration mix and shareholder-voting mechanics, with closing occurring in 2025.